AstraZeneca unveils $15bn China investment
29th Jan 2026 07:37
(Sharecast News) - AstraZeneca is to invest $15bn in China by the end of the decade, the UK drugs giant confirmed on Thursday, as part of the prime minister's visit to the country.
Read moreCiti starts AstraZeneca at 'buy', takes 'neutral' stance on GSK
27th Jan 2026 11:36
(Sharecast News) - Analysts at Citi initiated coverage of AstraZeneca and GSK on Tuesday, taking a bullish stance on the former but a more cautious view on the latter.
Read moreAstraZeneca chalks up dual regulatory wins in cancer and immunology
16th Dec 2025 07:42
(Sharecast News) - Drugmaker AstraZeneca chalked up two regulatory wins on Tuesday, with approvals in both the US and Europe for key treatments in oncology and immunology.
Read moreAstraZeneca secures US approval for Imfinzi in gastric cancer
26th Nov 2025 07:03
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that its Imfinzi asset has been approved in the US for use alongside standard FLOT chemotherapy in the treatment of adult patients with resectable, early‑stage and locally advanced gastric and gastroesophageal junction cancers.
Read moreAstraZeneca to spend $2bn in US manufacturing push
24th Nov 2025 07:01
(Sharecast News) - AstraZeneca is to invest $2bn ramping up manufacturing facilities in Maryland, America, the blue chip drugs giant said on Monday.
Read moreAstraZeneca receives FDA approval for expanded Koselugo usage
20th Nov 2025 07:12
(Sharecast News) - The US Food and Drug Administration has approved the expanded usage of AstraZeneca's Koselugo drug to adults with neurofibromatosis type 1 (NF1) - a rare, progressive, genetic condition that can impact every organ system.
Read moreDirector dealings: 3i execs buy the dip, AstraZeneca CFO offloads shares
14th Nov 2025 13:53
(Sharecast News) - London-listed companies 3i Group and AstraZeneca disclosed fresh director dealings on Wednesday, with senior executives at the private equity group adding to their holdings while AstraZeneca's finance chief sold American Depositary Shares.
Read moreAstraZeneca beats Q3 expectations, maintains FY outlook
6th Nov 2025 09:18
(Sharecast News) - Drugmaker AstraZeneca reiterated its full-year guidance on Thursday as it posted a third-quarter earnings beat, driven by solid sales of its cancer, heart and kidney disease drugs.
Read moreAstraZeneca's Koselugo receives EU approval
28th Oct 2025 07:03
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Koselugo asset has been approved for usage in the European Union for the rare, progressive, genetic condition, plexiform neurofibromas, in adults with neurofibromatosis type 1.
Read moreAstrazeneca's Tezspire secures EU approval
22nd Oct 2025 08:00
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that its chronic rhinosinusitis with nasal polyps treatment, Tezspire, has been approved in the European Union as an add-on therapy with intranasal corticosteroids for adults.
Read moreAstraZeneca lupus treatment gets EU approval
20th Oct 2025 07:03
(Sharecast News) - AstraZeneca has received the green light from European regulators for its Saphnelo treatment for lupus, the pharma giant announced on Monday.
Read moreDeutsche Bank downgrades AstraZeneca to 'sell'
16th Oct 2025 10:24
(Sharecast News) - Deutsche Bank downgraded AstraZeneca to 'sell' from 'hold' on Thursday and cut the price target to 10,500p from 11,500p as it said it was turning sceptical on SERENA-4.
Read moreAstraZeneca to cut US drug prices in key White House deal
13th Oct 2025 07:01
(Sharecast News) - AstraZeneca has struck a deal with the White House to cut drugs prices in America, allowing it to avoid steep tariffs on US imports.
Read moreAstraZeneca's Baxdrostat hits Phase III endpoint in resistant hypertension
7th Oct 2025 07:27
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that Baxdrostat had met its primary endpoint in the Bax24 Phase III trial, delivering a "statistically significant and clinically meaningful reduction" in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension.
Read moreLondon midday: Stocks mixed with French and US fiscal impasses in focus
6th Oct 2025 11:13
(Sharecast News) - Stocks in London were trading on a mixed note around the midday mark, but had stabilised despite news of the French Prime Minister's resignation after just a month on the job.
Read more